Figure 6.

Cost-effectiveness acceptability curve for rescue therapies for LAM-resistant HBeAg-positive (A) and HBeAg-negative (B) chronic hepatitis B. The y-axis indicates the probability that a therapy is cost-effective across willingness to pay per QALY gained (x-axis). The bold vertical two-dash and solid lines represent the thresholds for China and Shanghai City, respectively. Combination strategy uses LAM and ADV.

Wu et al. BMC Health Services Research 2012 12:385   doi:10.1186/1472-6963-12-385
Download authors' original image